News | March 30, 2026
Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
The presentations underscore the company’s deep expertise in dermatology and immunology
The presentations underscore the company’s deep expertise in dermatology and immunology
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
European operations' revenue grew 58.4% to Rs 599.7 crore
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
